German Adjuvant Intergroup Node-Positive Study: A Phase III Trial to Compare Oral Ibandronate Versus Observation in Patients With High-Risk Early Breast Cancer

Abstract

Adjuvant treatment with oral ibandronate did not improve outcome of patients with high-risk early breast cancer who received dose-dense chemotherapy.

NCCN Guidelines Insights: Breast Cancer, Version 1.2017

“…61 With respect to other bisphosphonates, one trial that studied adjuvant oral ibandronate showed no effect on DFS or OS in patients with node-positive, early-stage breast cancer treated with dose-dense chemotherapy. 62 Data on adjuvant oral pamidronate show no benefit on either reducing fractures or recurrence to bone in patients with breast cancer receiving adjuvant chemotherapy. 63 …”

Zoledronate for patients with invasive residual disease after anthracyclines-taxane-based chemotherapy for early breast cancer – The Phase III NeoAdjuvant Trial Add-oN (NaTaN) study (GBG 36/ABCSG 29)

“…In addition, recent subgroup analysis supports the hypothesis that bisphosphonate mainly works in oestrogen-deprived patients, i.e. patients at least 5 years into menopause or with ovarian function suppression [14,15]. Last but not least, the median followup of this study is too short to fully assess treatment effects in patients with hormone-receptor-positive/ HER2-negative tumours.…”

Assessment of influence of two regimens of intravenous administration of a klodronat on dynamics of a pain syndrome and quality of life of patients with breast cancer metastasises in skeleton bones

“…Abstract: Breast cancer is characterized by tendency to early metastasizing: about 6 % of patients already have metastatic form of the disease at the time of diagnosis. The most frequent target are bones: for the frequency of bone metastasis, breast cancer is on the second place among malignant tumors and on the first place in absolute incidence [1,2,3,4]. On the early stages, metastatic bone lesions can be asymptomatic.…”

“…Наиболее частой мишенью при этом являются кости (костная система): по частоте метастазирования в кости РМЖ занимает 2-е место среди злокачественных опухолей, а по удельному весу -1-е [1,2,3,4]. На ранних стадиях метастатическое поражение костей бывает бессимптомным [5,6].…”